# OnCo record aldoxorubicin-phase-3-sts (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/aldoxorubicin-phase-3-sts/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "aldoxorubicin-phase-3-sts", "NCT02049905" ;
  schema:name "Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma"@en ;
  schema:description "The phase 3 that was meant to bring the tumour-targeted doxorubicin aldoxorubicin to market: it did not meet its primary endpoint of progression-free survival."@en ;
  schema:url <https://onco.cc/trials/aldoxorubicin-phase-3-sts/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02049905>, <https://doi.org/10.1001/jamaoncol.2015.3101> ;
  onco:status "negative" ;
  onco:tag "owner-request" ;
  onco:phase "3" ;
  schema:startDate "2014-01" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/aldoxorubicin/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/pazopanib/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/dacarbazine/> ;
  onco:companies <https://onco.cc/companies/immunitybio/>, <https://onco.cc/companies/gemini-therapeutics/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-chawla-jama-oncol/> .